First mRNA flu vaccine wins FDA approval. A quiet revolution for pandemic preparedness
On 5 August 2026, the FDA approved Moderna's mFLUSIVA, the first mRNA seasonal flu vaccine. The decision is small in label and large in consequence, because the same platform that produced COVID-19 shots in months can now be redirected to a pandemic influenza strain in weeks.